137 related articles for article (PubMed ID: 12594577)
1. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients.
Koukourakis MI; Ktenidou-Kartali S; Bourikas G; Kartalis G; Tsatalas C
Cancer Immunol Immunother; 2003 Feb; 52(2):127-31. PubMed ID: 12594577
[TBL] [Abstract][Full Text] [Related]
2. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer.
Koukourakis GV; Baksevanis CN; Zambatis H; Gritzapis A; Maltezos E; Simopoulos C; Koukourakis MI
Int J Radiat Biol; 2009 Jan; 85(1):96-104. PubMed ID: 19205988
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
[TBL] [Abstract][Full Text] [Related]
4. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
Koukourakis MI; Yannakakis D
Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
[TBL] [Abstract][Full Text] [Related]
6. Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ T cells in peripheral blood derived from patients with autoimmune hepatitis or chronic hepatitis C with autoimmune phenomena.
Ogawa S; Sakaguchi K; Takaki A; Shiraga K; Sawayama T; Mouri H; Miyashita M; Koide N; Tsuji T
J Gastroenterol Hepatol; 2000 Jan; 15(1):69-75. PubMed ID: 10719750
[TBL] [Abstract][Full Text] [Related]
7. Amifostine modulates radio-induced apoptosis of peripheral blood lymphocytes in head and neck cancer patients.
Saavedra MM; Henríquez-Hernández LA; Lara PC; Pinar B; Rodríguez-Gallego C; Lloret M
J Radiat Res; 2010; 51(5):603-7. PubMed ID: 20699603
[TBL] [Abstract][Full Text] [Related]
8. Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery.
Manavis J; Ambatzoglou J; Sismanidou K; Koukourakis MI
Am J Clin Oncol; 2006 Oct; 29(5):479-83. PubMed ID: 17023783
[TBL] [Abstract][Full Text] [Related]
9. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
[TBL] [Abstract][Full Text] [Related]
10. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
[TBL] [Abstract][Full Text] [Related]
11. Influence of amifostine on reconstitution of lymphocyte subpopulations after conventional- and high-dose chemotherapy in patients with germ cell tumor.
Rick O; Beyer J; Schwella N; Siegert W
Ann Hematol; 2002 Dec; 81(12):717-22. PubMed ID: 12483368
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
[TBL] [Abstract][Full Text] [Related]
14. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
[TBL] [Abstract][Full Text] [Related]
15. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity.
Giatromanolaki A; Sivridis E; Maltezos E; Koukourakis MI
Semin Oncol; 2002 Dec; 29(6 Suppl 19):14-21. PubMed ID: 12577238
[TBL] [Abstract][Full Text] [Related]
17. Protection from radiation-induced apoptosis by the radioprotector amifostine (WR-2721) is radiation dose dependent.
Ormsby RJ; Lawrence MD; Blyth BJ; Bexis K; Bezak E; Murley JS; Grdina DJ; Sykes PJ
Cell Biol Toxicol; 2014 Feb; 30(1):55-66. PubMed ID: 24459009
[TBL] [Abstract][Full Text] [Related]
18. Radioprotective effects of amifostine.
Wasserman T
Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
[TBL] [Abstract][Full Text] [Related]
19. Prevention of radiation-induced central nervous system toxicity: a role for amifostine?
Nieder C; Andratschke NH; Wiedenmann N; Molls M
Anticancer Res; 2004; 24(6):3803-9. PubMed ID: 15736415
[TBL] [Abstract][Full Text] [Related]
20. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC).
Khodarev NN; Kataoka Y; Murley JS; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):553-63. PubMed ID: 15380592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
